Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

Shots:At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701PThe study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701PBiocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…

BySaurabh ChaubeyMarch 17, 2025

THOUGHTSPOT

EMA’s Battle Against Falsified Drugs in the Supply Chain

Introduction The pharmaceutical industry plays a critical role in global public health by ensuring the safety and efficacy of drugs. The European Medicines Agency (EMA) is tasked with safeguarding the European Union's pharmaceutical supply chain. However, concerns have been raised about the agency's ability to effectively address vulnerabilities to substandard or falsified drugs. This article…

ByJane DoeJune 6, 2024

VIEWPOINTS

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Shots:At the EASD, AZ announced positive results from the T2NOW P-III study that evaluated the efficacy and safety of Forxiga as an add-on treatment in children and adolescents with T2D receiving metformin, insulin, or bothHelen Yeh, VP, CVRM Therapy Area Biopharmaceuticals Medical at AstraZeneca, and Naim Shehadeh, Professor of Endocrinology, Rambam Health Care…

BySaurabh ChaubeyDecember 11, 2023

VIEWPOINTS

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

Shots: Jennifer Davidson, VP, of Medical Affairs Immunology, Johnson & Johnson Innovative Medicine shares insights from the data of the Phase III QUASAR induction study presented at the DDW'23 P-III QUASAR induction study 1 demonstrated positive results in patients who received TREMFYA 200 mg vs Placebo, with most of the patients achieving remission at week…

BySaurabh ChaubeyNovember 13, 2023

VIEWPOINTS

Dr. Jay Backstrom shares insights from the Phase II TOPAZ trial for the treatment of SMA

Shots: Dr. Jay Backstrom in an engaging conversation with PharmaShots, shares the highlights of the P-II Topaz trial designed to evaluate the safety and efficacy of apitegromab for the treatment of Spinal Muscle Atrophy (Type 2 & 3) With the potential to transform care in SMA by directly addressing progressive muscle weakness, apitegromab aims to…

BySaurabh ChaubeyNovember 7, 2023

VIEWPOINTS

Marija Geertsen shares highlights of the data presented at the 65th AHS Annual Meeting

Shots: Marija Geertsen shares the highlights of the data presented at the 65th AHS annual meeting, including insights from real-world experience with VYEPTI's review study With a focus on the review study that delved into the experiences of 94 patients receiving VYEPTI treatment, Marija provides an in-depth account of the PROMISE 1 and PROMISE 2…

BySaurabh ChaubeyNovember 6, 2023

VIEWPOINTS

Simon Portsmouth Shares Insights from P-III Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Shots:Simon spoke about the enrollment of the first participant in Japan in the P-III (SCORPIO-PEP) study to evaluate the safety and efficacy of Ensitrelvir for the prevention of symptomatic SARS-CoV-2 infectionHe mentioned how this study will supplement data from the pivotal SCORPIO-SR trial's P-III segment which showed ensitrelvir's effectiveness in treating mild-to-moderate COVID-19…

BySenior EditorSeptember 18, 2023

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

EMA’s Battle Against Falsified Drugs in the Supply Chain

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

Dr. Jay Backstrom shares insights from the Phase II TOPAZ trial for the treatment of SMA

Marija Geertsen shares highlights of the data presented at the 65th AHS Annual Meeting

Simon Portsmouth Shares Insights from P-III Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

Contact US

OUR INFORMATION

FOLLW US

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

EMA’s Battle Against Falsified Drugs in the Supply Chain

Helen Yeh & Naim Shehadeh in a Stirring Conversation with PharmaShots, Highlight the Results from T2NOW Study

Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

Dr. Jay Backstrom shares insights from the Phase II TOPAZ trial for the treatment of SMA

Marija Geertsen shares highlights of the data presented at the 65th AHS Annual Meeting

Simon Portsmouth Shares Insights from P-III Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection

FOLLW US

Sign Up to Our Newsletter